Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Reata Pharma (NQ: RETA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Reata Pharma

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 37 stocks hit new 52-week lows. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
FDA Pushes Decision Date For Reata's Genetic Neuromuscular Disease Candidate
Via Benzinga
Recap: Reata Pharmaceuticals Q2 Earnings
  Reata Pharmaceuticals (NASDAQ:RETA) reported its Q2 earnings results on Monday, August 8, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Baird Maintains Neutral Rating for Reata Pharmaceuticals: Here's What You Need To Know
  Baird has decided to maintain its Neutral rating of Reata Pharmaceuticals (NASDAQ:RETA) and lower its price target from $37.00 to $27.00. Shares of Reata Pharmaceuticals are trading down 8.1% over... 
Via Benzinga
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday. 
Via Benzinga
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
  
Via Benzinga
Dow, Nasdaq Enjoy Triple-Digit Gains Midday
Stocks are extending this morning's gains. 
Via Talk Markets
Why CinCor Pharma Is Trading Higher By 63%, Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Bonso Electronics International Inc. (NASDAQ: BNSO) shares jumped 132% to $11.12 after jumping around 46% on Friday. The company recently said it expects unaudited comprehensive loss of $1.6... 
Via Benzinga
Dow Jumps Over 150 Points; Karuna Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?
Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia. 
Via Benzinga
Why U.S. Stocks Are Trading Higher; Tyson Foods Earnings Miss Views
U.S. stocks traded higher this morning, following the release of strong jobs data on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
  
Via Benzinga
Reata Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
From Reata Pharmaceuticals, Inc.
Via Business Wire
Earnings Scheduled For August 8, 2022
Companies Reporting Before The Bell • Pyxis Tankers (NASDAQ:PXS) is likely to report earnings for its second quarter. 
Via Benzinga
Reata Pharmaceuticals Earnings Preview
Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that Reata... 
Via Benzinga
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
From Reata Pharmaceuticals, Inc.
Via Business Wire
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
From Reata Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday. 
Via Benzinga
Reata Pharmaceuticals Earnings Perspective: Return On Capital Employed
According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84... 
Via Benzinga
Where Reata Pharmaceuticals Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Pharma Stock Shoots Up As FDA Accepts NDA For Neuromuscular Disorder Drug Under Priority Review
Reata Pharmaceuticals (NASDAQ: RETA) announced that the U.S. Food and Drug Administration has accepted New Drug Application (NDA) for its lead drug candidate omaveloxolone for the treatment of patients... 
Via Benzinga
The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
From Reata Pharmaceuticals, Inc.
Via Business Wire
NASDAQ:RETA Long Term Shareholder Notice: Investigation over Possible Wrongdoing at Reata Pharmaceuticals, Inc.
San Diego, CA -- (SBWIRE) -- 05/10/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Reata Pharmaceuticals, Inc. 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.